Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Pozycja w akcjach
#3422
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Cena akcji
$4.48
Kapitalizacja rynkowa
$4.99B
Zmiana (1 dzień)
-5.20%
Zmiana (1 rok)
-41.89%
Kraj
CN
Handel Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Kategoria
Healthcare
Wskaźnik P/B dla Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Wskaźnik P/B na dzień October 2026 TTM: 3.88
Według najnowszych raportów finansowych i ceny akcji Shenzhen Salubris Pharmaceuticals Co., Ltd., obecny wskaźnik P/B (TTM) wynosi 3.88. Na koniec 2024 wynosił 3.96.
Historia wskaźnika P/B dla Shenzhen Salubris Pharmaceuticals Co., Ltd. od 2006 do 2026
Wskaźnik P/B na koniec każdego roku
| Rok | Wskaźnik P/B | Zmień |
|---|---|---|
| 2026 (TTM) | 3.88 | -37.25% |
| 2025 | 6.18 | 56.35% |
| 2024 | 3.96 | -12.84% |
| 2023 | 4.54 | -0.14% |
| 2022 | 4.54 | 25.18% |
| 2021 | 3.63 | -31.38% |
| 2020 | 5.29 | 65.13% |
| 2019 | 3.20 | 5.19% |
| 2018 | 3.05 | -57.11% |
| 2017 | 7.10 | 24.43% |
| 2016 | 5.71 | -16.88% |
| 2015 | 6.86 | 12.33% |
| 2014 | 6.11 | -14.97% |
| 2013 | 7.19 | 11.94% |
| 2012 | 6.42 | 55.67% |
| 2011 | 4.12 | -53.03% |
| 2010 | 8.78 | 74.01% |
| 2009 | 5.05 | -76.40% |
| 2008 | 21.39 | -44.68% |
| 2007 | 38.66 | -13.03% |
| 2006 | 44.45 | 0.00% |
Wskaźnik P/B dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/B | Różnica wskaźnika P/B | Kraj |
|---|---|---|---|
| 9.3984 | 142.36% |
US
|
|
| 2.0545 | -47.02% |
FR
|
|
| 8.6921 | 124.14% |
JP
|
|
| 2.1872 | -43.60% |
US
|
|
| 1.5197 | -60.81% |
CH
|
